FB704A

Phase 2Biologic

OOneness Biotech Co., Ltd.

FB704A is one of 22 biologic programs targeting Asthma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AsthmaActive, not recruiting

Severe AsthmaCompleted

AsthmaPhase 2

Active, not recruiting

Severe AsthmaPhase 2

Completed

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Cinqair

Teva

Preclinical

13 2

Qvar

Chiesi Farmaceutici S.p.A.

Preclinical

8 3

Spiriva

Boehringer Ingelheim

Preclinical

8 4

Atrovent

Boehringer Ingelheim

Preclinical

5 5

Formoterol Fumarate

AstraZeneca

Preclinical

8 6

FB704A

OOneness Biotech Co., Ltd.

Phase 2

2 7

Symbicort

AstraZeneca

Preclinical

6 8

Aciphex

Akero Therapeutics

Preclinical

2 9

Tylenol

KKenvue Brands

Preclinical

1 10

Paracetamol

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tics1 trial

Evaluate the Safety, Tolerability, Pharmacokinetics,and Clinical Activity of FB704A

Completed·FFountain Biopharma Inc.·Phase 1·NCT03890302·31 enrolled

Severe Asthma1 trial

A Randomized, Placebo Controlled, Double Blind Phase IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Multiple Intravenous Doses of FB704A in Adults With Severe Asthma

Completed·OOneness Biotech Co., Ltd.·Phase 2·NCT05018299·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for FB704A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FB704A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FB704A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Oneness Biotech Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: OOneness Biotech Co., Ltd.

FB704A

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tics1 trial

Severe Asthma1 trial

References

Drug Info

Quick Facts

Related News